Author

Caroline Brard

Observed names: Brard, Caroline, C. Brard

Observed institutions: Université Paris-Sud, Inserm, Ipsen (France), Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, Institut Gustave Roussy, Centre de recherche en Epidémiologie et Santé des Populations, Fondation Gustave Roussy

ORCID: 0000-0002-0196-4157

Observed ORCID: 0000-0002-0196-4157

OpenAlex ID: A5068293277

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

2021 · Claudia Pasqualini, Jonathan Rubino, et al. · European Journal of Cancer · 57

PDF

Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma

2019 · Caroline Brard, Sophie Piperno-Neumann, et al. · BMJ Open · 50

PDF

Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial

2021 · Francisco Bautista, Xavier Paoletti, et al. · Journal of Clinical Oncology · 35

Bayesian survival analysis in clinical trials: What methods are used in practice?

2016 · Caroline Brard, Gwénaël Le Teuff, et al. · Clinical Trials · 35

First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial

2021 · Raphael J. Morscher, Caroline Brard, et al. · European Journal of Cancer · 34

PDF

A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

2021 · Isabelle Girault, Julien Adam, et al. · Clinical Cancer Research · 28

Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre

2017 · Margarida Matias, Gwénaël Le Teuff, et al. · European Journal of Cancer · 27

Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials

2019 · J. Guigay, A. Auperin, et al. · Annals of Oncology · 21

Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial

2023 · Susanne A. Gatz, Anne C. Harttrampf, et al. · Clinical Cancer Research · 19

PDF

Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study

2019 · Caroline Brard, Lisa V. Hampson, et al. · BMC Medical Research Methodology · 17

PDF

Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.

2021 · Judith Michels, François Ghiringhelli, et al. · Journal of Clinical Oncology · 4

PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer.

2022 · Judith Michels, François Ghiringhelli, et al. · Journal of Clinical Oncology · 2

Bayesian generalized method of moments applied to pseudo-observations in survival analysis

2025 · Léa Orsini, Caroline Brard, et al. · Lifetime Data Analysis · 1

Bevacizumab exposure and tumor response in patients with platinum resistant epithelial ovarian cancer.

2023 · Judith Michels, Mourad Hamimed, et al. · Journal of Clinical Oncology · 1

Abstract CT087: Phase I/II study of the WEE1 inhibitor adavosertib in combination with carboplatin in children with advanced malignancies: arm C of the AcSé-ESMART trial

2023 · Susanne A. Gatz, Anne C. Harttrampf, et al. · Cancer Research · 1

355 Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients

2021 · Judith Michels, Jean-Sebastien Frenel, et al. · Journal for ImmunoTherapy of Cancer · 1

PDF

Semi-ResMass Study: Residual masses after salvage chemotherapy in men with pure seminoma—A multicenter retrospective analysis.

2020 · Giulia Baciarello, Caroline Brard, et al. · Journal of Clinical Oncology · 1

PDCT-05. FINAL RESULTS OF THE VINILO OPEN-LABEL PHASE II RANDOMIZED TRIAL FOR PEDIATRIC LOW-GRADE GLIOMAS (pLGG) COMPARING THE COMBINATION VINBLASTINE-NILOTINIB WITH VINBLASTINE ALONE

2019 · Jacques Grill, Caroline Brard, et al. · Neuro-Oncology · 1

PDF

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin (API), followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Update at 10 years

2017 · P. Pautier, C. Brard, et al. · Annals of Oncology · 1

Supplementary Figure S1 from Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial